Aseptic challenges: the experts' view - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Aseptic challenges: the experts' view
Leading pharmaceutical experts talk to Pharmaceutical Technology Europe about trends and challenges in aseptic techniques and technologies.

Pharmaceutical Technology Europe
Volume 21, Issue 12

What have been the key innovations that have shaped current aseptic practices and techniques?

Jerold Martin
Henderson: The number one consideration for aseptic practices and technique is risk minimization. Since the mid-1990s, the development of isolators and restricted access barrier systems (RABS) has substantially changed how operators interact with sterile drug product and their associated technique. A physical barrier between the operator and the critical zone of the isolator controlled at positive pressure with HEPAfiltered air creates a high level of contamination control. Most interactions through isolators and RABS are done through glove ports, which again limits the risk to the associated product. In addition, the ability to biodecontaminate the critical zone and clean-in-place/steam-in-place (CIP/SIP) contact parts has led to less operator involvement and further reduces risk. Magriotis: Isolation technology is replacing conventional clean room aseptic technology within the most developed areas of the pharmaceutical industry. The technology's major benefit is the higher aseptic conditions that can be achieved and maintained during manufacturing. Isolators provide a complete barrier between product and operators, who are the highest source of contamination in aseptic processing. Isolators also guarantee a higher sterility assurance level after decontamination compared with conventional clean room technology (usually 6 Log contaminants reduction versus 3 Log reduction). This is achieved by means of vaporized hydrogen peroxide.

(George Doyle/Getty Images)
Furthermore, in 2008, the European Commission issued a GMP document for sterile drugs preparation stating that the sealing of sterile vials with aluminium caps must happen under Grade A laminar air flow. Consequently, the most innovative machinery manufacturers have reviewed the design of their aluminium capping machines; the latest models incorporate features that make them suitable to work under laminar air flow and that minimize particle generation to maintain the required level of air cleanliness. Martin: Key innovations have been singleuse systems (processscale filter capsules, tubing, biocontainers, etc.), which are presterilized (by gamma irradiation) and preassembled to eliminate aseptic connections and cleaning. These systems have been further enabled by the introduction of sterile connectors. Use of singleuse systems and sterile connectors reduces risk of both microbial contamination and chemical contamination from lottolot or producttoproduct carryover or from cleaning agent residues. Because they are closed systems, they can even enable sterile processing to be done outside of isolators or Class A environments.

David Henderson Jr
Another key innovation is the development of new high capacity 0.1Ám-rated filters with high mycoplasma removal capability. These are used for sterilizing filtration of soy peptonebased bacterial culture media used in aseptic filling line validation to ensure the absence of mycoplasma, such as Acholeplasma laidlawii, in the sterile media fill validation of the aseptic filling line.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here